Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm in at .67 - another financial that just got the living #@## kicked out of it.. looking for a rebound
I listened to the earnings call, they did loose some $$$$ from top deposits but they are still giving out loans as previous stated and noted in todays PR.
I also read a nice article about a week ago regarding Real Estate market in CA, NV and UTAH ( Majority of SSBX's loan base ) that indicators are showing a turn around.
I can not find the link but will post if I do.
If housing and real estate data in these states starts to turn positive this stock will fly.....
Great entry point IMO
nice to see you in... I picked up some at .67--- looking for a nice BIG bounce hopefully--- with some volume the PPS could easily shoot back up over $1.00 IMO --- moves fast
SSBX - up to .72 volume starting to pick up
lets see if it can gain some steam..
SSBX - looks ready for rebound / down settling nice at .65 - .70
have been watching since last week - down 70%
missed INAP for 1.75, waiting to see if dips again around 1.80
excuse me, I meant 2.75 and 2.80...
I'd be really happy if I did get it at 1.75
jumped out 1 minute after news came out...
wait until west coast wakes up for further drop
could see below $1 level today
thanks again Board for the CSK pick..
in at .78 out today at 1.43 YOU GUYS ROCK!!!!!
any thoughts on BKHM -
has a history of 20-30% bounces
last earnings were not bad
4Q loss 2c share vs 17c loss previous 4Q
Rev $62.5M vs $45.1M
down from $2.00 2 Fridays ago
Hey, nice call boys on CSK, I followed you and picked some up on Friday at .78 and still holding...
making a nice run today in a crappy market
any other oil plays you following
I wish I had took some more back down there
like to see .15 today!!!
surf -
in your experience is a positive run up like we are seeing any indication at all of the FDA decision?
We seem to be moving pretty good. Your thougts?
by the way, nice call on this one..
starting to gain some attention, over 25% of daily volume in the 1st 45 minutes, daily high 3.78 -
the yahoo board for VNDA is crazy busy....
I had asked if based off the results did they still feel this well was a " company maker " as previously stated in last PR.
He stated that they are not done logging the results ( which could be done today ) Without the complete logging results I'm sure he can't say one way or the other. IMO
I emailed the company using the info@universalenergycorp.ingo
and got a response from Bill in less than 20 minutes.
The drilling at Lone Oak is complete here is his response, unedited:
The drilling is complete. We have spent the last two days trying to log, but due to equipment and weather issues we have not completed the log.
We hope to complete it today.
Lone Oak will indeed have a very positive impact on our revenues if it is a good well. If it is not good, it will not impact the company negatively as we have already paid for this well. We will start another well.
Thanks
Billy Raley
Chief Executive Officer
Universal Energy Corp.
30 Skyline Drive
Lake Mary, Fl. 32746
T - 800.975.2076
F - 800.805.4561
braley@universalenergycorp.info
we need some volume to move this, the best way to bring in the volume is the PR everyone is expecting
Why was the CEO's email address removed?
I just got off the phone with an old college buddy, T. Boone Pickens. He told me to BUY BUY BUY UVSE!!!!
Another one:
Ilo- QT impact- my research shows no impact 2-Jul-08 05:37 pm
So - I did lots of reading today at FDA website.
Per their QT Guideline doc - Ilo should not have any problems with QT prolongation.-
Per Guideline doc- QT < 20msec are inconclusive , but some of these compounds have been associated with proarrhythmic risk. Also, looking at a few other drugs with QT prolongation on FDA site- even for instances of QT>500msec.... if the occurrence of >500msec is less than 1% - Drugs still approved with QT labelling. Ilo NDA had 3000 patients... so the 2 patients identified in early studies with >500msec are fairly irrelevant as pertains to approval.... (IMO).
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_V/threadview?m=tm&bn=28025&tid=6669&mid=6669&tof=1&frt=2
Interesting post from yahoo.
There is no mention of where this was published, if it was at all. Some very good points made in this post.
Here it is:
Within six months, Vanda Pharmaceuticals VNDA will face an approval decision for lead drug candidate Iloperidone, a treatment for schizophrenia. While we're sticking with our fair value estimate for now, we'll almost certainly adjust it after the Food and Drug Administration renders its final verdict. If regulators approve Iloperidone, we'll raise our fair value estimate by as much as $8 per share; if they don't, we'll cut it by more than two thirds.
Vanda's future hinges almost entirely on Iloperidone. With its stock trading at depressed levels, the firm may not be able to raise additional capital until after the FDA makes its final decision on Iloperidone, which, coincidentally, is right around the time the firm's cash balance will run out. While Vanda has two drugs for sleep disorders in its pipeline, we're not big fans of either and think the company will have a difficult time raising funds on the promise of those candidates alone. Given the recent stock price, the market is forcing Vanda's hand: Either raise funds now and dilute shareholders but ensure access to capital whether or not Iloperidone is approved, or don't raise funds now and bet everything on an Iloperidone approval. Given its recent decision to abandon a convertible debt offering because of unattractive terms, we think Vanda is favoring the latter.
We think Iloperidone's chances for approval are high. Before Vanda acquired the compound, Novartis NVS conducted three Phase III trials for Iloperidone, to mostly mixed results. While Iloperidone improved symptoms of schizophrenia at higher doses, its benefits failed to reach statistical significance at lower doses. In addition, at these higher doses, the drug was shown to prolong the heart's QTc interval in patients, a potentially serious side effect. However, all of this was known before Vanda bought the compound, and it approached its development of the drug from an entirely different framework.
Using whole-genome association studies, Vanda found genetic mutations that correlate with patient responses to Iloperidone. As a result, through a blood test, Vanda can predict which patients will benefit most from treatment. In Vanda's Phase III trial for Iloperidone, while the overall group showed statistically significant improvement in symptoms, the benefits fell mainly to patients with the genetic markers, including a reduction in the prolongation of the QTc interval. Armed with this data, Vanda may side-step regulators' potential concerns about Iloperidone's safety by requiring a blood test for each patient. By marketing the drug to patients with specific genetic markers, Vanda could appeal to the clear need for more personalized schizophrenia medicines, since 75% of schizophrenia patients discontinue drug treatment before 18 months.
We think investors with a big appetite for risk have the right odds to call the market's all-or-nothing bet on Vanda.
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_V/threadview?m=tm&bn=28025&tid=7839&mid=7839&tof=2&frt=2
A nice after close PR would torch the fuse for tommorrow morning!!!! Lets rock!!!!
nice bounce back up, just shaking out weak hands IMO
would like to see some larger volume heading into this weekend
good luck VNDA players
Hello Vanda fans,
good buy sell ratio today, was a bit worried we might see some selling off and the bad news from Merck and SGP -
can anyone tell me about the FDA date of 7/27 -
is this just an estimated date or will news of the drug for sure be out on this date?
let's go Lone Oak, lets go!!!!!!!!!!!
Very interesting play here.
Does anyone know when the results of the FDA review will be complete. I thought I read somewhere on July 28th.
If Iloperidone is approved this stock is going to fly, if there is hold backs looks like additional funding might be an issue.
I'm in today at $3.53 - seems to me the risk/reward factor looks too damn good..... GO VANDA!!!
thanks for the info,
i'll wait and see if it holds
Could someone post a chart for NOBL and thoughts... thinking about jumping in
looks like starting to turn
starting to move now
Bid .13 Ask.14
376K volume..... move this dog
Can someone else confirm.
Share structure can not change until next BOD meeting, which is not held until sometime mid Aug???
If so we have almost 1 month with no dillution???
That could put us in for a HUGE RUN IMO
Is anyone paying attention to this stock.
Volume is startig to rise as well as the PPS. Here was the last PR.
General Metals Discovers New High Grade Zone Expanding Original Mineralized Target Estimates
RENO, NV (OTCBB: GNMT) (Frankfurt: GMQ) announces the discovery of new high grade mineralization north of the Canyon Fault including 15 feet grading 0.324 ounces of gold equivalent per ton (opt Au Equiv.).
Drilling north of the Canyon Fault identified two parallel zones of mineralization, unlike the Independence Shallow Target which is dominated by a single mineralized zone at the south end of the property. This significant new discovery increases the exploration potential for near surface mineralization substantially over the originally estimated target potential, resulting in what the Company feels, represents an important addition to oxide gold mineralization in the Battle Mountain Mining District of Nevada.
"Importantly there is no historic mining north of Section 3400 North and as a result there is no depletion of high grade mineralization in the large northern target areas," said Steve Parent, Company President and CEO. "With this exciting new discovery of multiple, parallel, mineralized zones containing high grade mineralization north of the Canyon Fault it appears the Independence Mine is clearly an important discovery in the Battle Mountain District. The target zone for surface mineralization at the Independence is now more than one mile long and open to depth. Drilled mineralization is limited only by the drilling accomplished to date, is open on strike and to depth."
Holes GM 54, the first hole drilled north of the Canyon Fault on Section 3400 North, as well as 55 and 56 drilled on Section 4000 North, roughly 800 feet north of the Canyon Fault and 600 feet north of hole GM-54 tested the Company's exploration model north of this fault structure. Historically this fault was considered the termination or "cut off" of the mineralized Independence Zone. Despite promising soil geochemistry and strong surface alteration, limited drilling was completed by others north of the Canyon Fault in the past. Review of data from previous operators and modeling by the Company's geologists indicated excellent potential north of this fault.
The outcomes which includes high grade intercepts of 15 feet grading 0.324 opt Au Equiv. and five feet grading 0.266 opt Au Equiv. in GM-56 are contained within a larger 90-foot intercept grading 0.076 opt Au Equiv.
"These results confirm the geologic interpretation by our professionals," continues Steve Parent. "We are extremely pleased and encouraged that, thus far we have achieved a 100% success rate, with virtually every hole of the 56 holes in the Company's combined 2007 - 2008 drill program encountering mineralization of potential ore grade over potentially mineable widths."
Drill results north of the Canyon fault thus far, appear shallower, higher grade and wider than the mineralization south of the fault. Unlike the mineralization drilled south of the Canyon Fault, which is dominated by a single mineralized zone, drilling to the north of the fault appears to identify two parallel, well mineralized zones.
Dan Forbush CFO added, "The Company's exploration team, after successfully drilling and modeling mineralization on the southern portion of the property stepped across this fault with these first three holes and successfully tested mineralization north of this fault. Once again our commitment to this project and its potential is rewarded. We expect expansion of the mineralization to continue."
The following Table presents the salient drill data from the holes discussed in this press release.
Gold
Mineralized Intercepts Equivalent
------------------------------------------------ -------------
oz/t g/t
From To Intercept Gold Gold Silver Silver Au Au
Drill Hole (ft) (ft) (ft) oz/t g/ton oz/t g/ton Equiv. Equiv. ----- ----- --------- ----- ------ ------ ------ ------ ------ GM-54 140 240 100 0.022 0.68 0.20 6.13 0.026 0.80
----- ----- --------- ----- ------ ------ ------ ------ ------
Including 155 200 45 0.037 1.15 0.20 6.25 0.041 1.27
----- ----- --------- ----- ------ ------ ------ ------ ------
Also 410 440 30 0.009 0.28 0.24 7.37 0.013 0.42
----- ----- --------- ----- ------ ------ ------ ------ ------
GM-55 250 300 50 0.019 0.59 0.25 7.71 0.024 0.74
----- ----- --------- ----- ------ ------ ------ ------ ------
Also 465 520 55 0.015 0.47 0.07 2.18 0.016 0.51
----- ----- --------- ----- ------ ------ ------ ------ ------
GM-56 125 245 120 0.013 0.42 0.34 10.70 0.020 0.62
----- ----- --------- ----- ------ ------ ------ ------ ------
Including 175 195 20 0.021 0.65 0.73 22.67 0.035 1.08
----- ----- --------- ----- ------ ------ ------ ------ ------
GM-56 355 445 90 0.073 2.27 0.15 4.51 0.076 2.36
----- ----- --------- ----- ------ ------ ------ ------ ------
Including 355 370 15 0.317 9.86 0.38 11.73 0.324 10.08
----- ----- --------- ----- ------ ------ ------ ------ ------
and 435 440 5 0.264 8.21 0.11 3.55 0.266 8.28
----- ----- --------- ----- ------ ------ ------ ------ ------
Note: All notations of "t" and "ton" refer to a US "short" ton weighing 2000 pounds. All gold equivalent is calculated at a gold price of $800 (US) and a silver price of $15 per ounce, and does not consider variations which may exist in metallurgical recovery.
Section 3400 North
Hole GM-54 successfully encountered 100 feet grading 0.026 opt Au Equiv on the north side of the fault. A second zone of mineralization from 410 to 440 feet was encountered which graded 0.013 opt Au Equiv. This zone of low grade mineralization seems to correspond with larger stronger zones of mineralization encountered in holes GM 55 and 56 drilled 600 feet north on Section 4000 North.
Section 4000 North
Holes GM-55 and 56 tested targets identified by the Company's consultants and intersected two mineralized zones. Each zone contains similar or higher grade mineralization over equal or greater widths than found in the Independence Shallow Zone south of the Canyon Fault.
The mineralized zones continue to exhibit excellent continuity along strike and to depth. Drilling by the company has demonstrated oxide mineralization over a vertical range of 700 feet of elevation, in the near surface targets. Historic drilling by Noranda and Great Basin Gold indicate a total vertical range of the mineralized system in excess of 3,000 vertical feet. The geometry of the mineralized zones suggest this near surface oxidized mineralization potentially amenable to mining by open pit methods.
"Oxidized ores characteristically are amenable to low cost recovery techniques such as heap leaching. The grade of mineralization encountered in the Company's drilling to date are comparable with the grades of mineralization found in other operating open pit, heap leach mines in the State of Nevada today," stated Dan Forbush. "The presence of significant high grade mineralization in the northern drill sections enhances the economic potential of the property because the mineralized zone appears to be both shallower and larger than in the southern area.
A detailed description of the exploration and production history of the Independence property is available on the Company's web site at www.gnmtlive.com.
Durect receives FDA Oprhan Drug Designation
ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
49 minutes ago - Pr Newswire
Related Companies
Symbol Last %Chg
DRRX 3.90 1.96%
As of 9:49 AM ET 6/30/08
DURECT Corporation (Nasdaq: DRRX) announced today that the US Food and Drug Administration (FDA) has granted to DURECT orphan drug designation for bupivacaine for relief of persistent pain associated with post-herpetic neuralgia (PHN). Bupivacaine is the active pharmaceutical ingredient in ELADUR(TM), DURECT's investigational transdermal drug patch. If ELADUR is the first bupivacaine product approved for PHN, under the 1983 Orphan Drug Act ELADUR will receive seven years of market exclusivity following the approval of the product by the FDA.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)
"The receipt of orphan drug status enhances the product opportunity for ELADUR, including providing a more favorable development pathway," stated James E. Brown, DVM, President and CEO of DURECT. "We are continuing to develop ELADUR as a potentially best in class transdermal product for those suffering from PHN."
ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application, as compared to a wearing time limited to 12 hours with currently available anesthetic patches (e.g., Lidoderm(R), an FDA-approved lidocaine patch for post-herpetic neuralgia pain management). Bupivacaine, the active agent in ELADUR, is a potent, FDA-approved long-acting local anesthetic used in regional anesthesia for local tissue infiltration, nerve block, and epidural and intrathecal anesthesia. DURECT currently retains full commercial rights to this product candidate.
DURECT has previously announced positive results for ELADUR from a 60 patient Phase IIa clinical trial of patients suffering from post-herpetic neuralgia. In this study, ELADUR showed improved pain control versus placebo during the 3-day continuous treatment period. In addition, ELADUR appeared to be well tolerated overall, and patients treated with ELADUR and placebo exhibited similar safety profiles. A poster describing this study was presented at the 27th Annual Scientific Meeting of the American Pain Society on May 8, 2008 and is accessible on our website (http://www.durect.com/wt/durect/page_name/Publications).
Here is what REMOXY means to Durect:
We will receive payments if certain development and regulatory milestones are achieved. We also receive reimbursement for our research and development efforts on Remoxy and a manufacturing profit on our supply of key product excipients for use in Remoxy. In addition, if Remoxy is commercialized, we will receive royalties for Remoxy of between 6.0% to 11.5% of net sales depending on the sales volumes.
Help pay down debt and fund future pipeline --- Keep your eye on this company this year.... Check out their pipeline at:
http://www.durect.com/wt/durect/page_name/development
Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
25 minutes ago - Primenewswire
Related Companies
Symbol Last %Chg
KG 9.30 -1.06%
PTIE 8.21 -0.36%
As of 9:48 AM ET 6/10/08
Pain Therapeutics, Inc. (Nasdaq:PTIE) and King Pharmaceuticals, Inc. (NYSE:KG) today announced that a New Drug Application (NDA) for Remoxy(tm) has been submitted to the U.S. Food and Drug Administration (FDA). Remoxy, a unique long-acting formulation of oral oxycodone for moderate to severe chronic pain, is designed to resist common methods of prescription drug misuse and abuse.
Pain Therapeutics and King believe the NDA for Remoxy benefits from years of rigorous and independent scientific and clinical testing. The NDA includes animal and human data from extractability, pharmacokinetic, toxicology and clinical studies. If approved, the Companies believe Remoxy could be the first oxycodone on the market that is designed to reduce the risk of misuse and abuse.
"Our vision is to develop a line of opioid painkillers that minimize the risk of misuse, abuse or diversion," said Remi Barbier, Pain Therapeutics' chairman, president and chief executive officer. "We believe the integrity of such drugs can deliver peace of mind to physicians, pharmacists and patients."
Brian A. Markison, King's chairman, president and chief executive officer, stated, "The NDA submission for Remoxy is an important advance in meeting the pain management needs of patients and prescribers concerned with addressing the risks of prescription pain medicine misuse and abuse within our communities."
About the NDA for Remoxy
Pain Therapeutics submitted the NDA in accordance with the FDA's Electronic Common Technical Document specifications. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, the FDA is expected to determine whether to accept the NDA for filing within 90 days. At that time the Companies will also learn if the NDA filing was granted priority review. A Priority Review designation is given to drugs that offer real advances in treatment, or provide a treatment where no adequate therapy exists. A Priority Review means that the time it takes FDA to review a NDA is reduced from 12 months to approximately 6 months.
This should be a good week for Durect - hopefully good news
DURECT Corporation to Participate in Upcoming Healthcare Conferences
Friday 06/06/2008 8:45 AM ET - Pr Newswire
As of 4:00 PM ET 6/6/08
DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming life sciences conferences in New York, NY.
-- Needham & Company's Biotechnology and Medical Technology Conference on
Thursday, June 12th at 11:30 a.m. EDT.
-- Leerink Swann's Pain Roundtable Conference, on Monday, June 23rd at
12:45 p.m. EDT.
-- Jefferies' 2nd Annual Healthcare Conference on Thursday, June 26th at
10:45 a.m. EDT.
Press Release Source: Orthovita, Inc.
Orthovita to Present at the Needham & Company, LLC Seventh Annual Biotechnology and Medical Technology Conference
Tuesday June 3, 5:00 pm ET
MALVERN, Pa.--(BUSINESS WIRE)--Orthovita, Inc. (NASDAQ:VITA - News), a spine and orthopedic biosurgery company, announced today that it will present at the Needham & Company, LLC Seventh Annual Biotechnology and Medical Technology Conference in New York. Antony Koblish, chief executive officer of Orthovita, is scheduled to present on Thursday, June 12th, at 2:30 p.m. Eastern Time, at The New York Palace Hotel, 455 Madison Avenue, New York, NY. A live audio webcast of the presentation will be available, and can be accessed for 90 days following the conference, by visiting http://www.wsw.com/webcast/needham25/vita.
I have been watching since last October and have been following Jeff Gendell with his plays. Picked some up in late November. Also check out Miscor.
Posted by: moneytalksbswalks Date: Wednesday, October 31, 2007 10:09:17 PM
In reply to: dffhogs who wrote msg# 11 Post # of 25
When I saw that Jeff Gendell bought 27m shares a few months ago I thought this baby was going to fly.... I let it slip away and never bought any. Now look at this baby move.
When Jeff Gendell buys into a stock, it turns to GOLD!!!!
For those that own shares enjoy the ride!!!!
http://biz.yahoo.com/t/40/433.html
here is some other companies Gendell and his investment firm, Tontine Associates LLC..
This guy knows what he is doing.